Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
Open, non-randomised, radiolabelled, single centre study with a total of six patients with
solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and
its metabolites.